Neurological & CognitiveResearch OnlyS

DSIP

Delta Sleep-Inducing Peptide

Delta sleep-inducing peptide (DSIP) is a nonapeptide first isolated in 1977 from thalamic perfusate of sleeping rabbits by Monnier et al. that induced slow-wave (delta) sleep when infused. Subsequent research has explored roles in pain modulation, stress response, temperature regulation, and antioxidant effects. Clinical evidence is limited and inconsistent; mechanism remains poorly characterized. Research only.

XRedditFacebook
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
Studies cited
3
Research grade
S
Community score
103

Trend index

Trackers
1,902

Overview

About DSIP

Delta sleep-inducing peptide (DSIP) is a nonapeptide first isolated in 1977 from thalamic perfusate of sleeping rabbits by Monnier et al. that induced slow-wave (delta) sleep when infused. Subsequent research has explored roles in pain modulation, stress response, temperature regulation, and antioxidant effects. Clinical evidence is limited and inconsistent; mechanism remains poorly characterized. Research only.

Category
Neurological & Cognitive
Regulatory status
Research Only
Also known as
Delta Sleep-Inducing Peptide
Self-reports
49

Community

What 49 users report

49 community reports

Positive 3% · Neutral 97% · Negative 0%

Most reported benefits

Sleep
182
Mood
182

Most reported side effects

Headache
177

Dose distribution

Median: 200–400 mcg · Most common: 200–400 mcg

0–25
0
25–50
5
50–100
2
100–200
38
200–400
131
400–600
6
600–1000
0
1000–2000
0
2000+
0

How repeat users are trending

Among repeat reporters, 85% said they felt similar to their last entry, 15% more positive, and 0% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 62 days · Based on 33 repeat reporters

Research

Cited research (2)

Help

Frequently asked

What do PeptIQ users report about DSIP?

This page summarizes 49 anonymized self-reports from PeptIQ users who track DSIP, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.

What research is cited for DSIP?

2 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.

Is DSIP safe to use?

This wiki does not assess safety or recommend use. DSIP is listed as Research Only. Consult a licensed clinician for personal medical decisions.

What are the purported benefits and uses of DSIP?

Research, primarily in animal models, suggests DSIP may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.

Source

What is the legal status of DSIP?

DSIP is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified DSIP as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.

Source

What are the known or theoretical side effects and risks of DSIP?

The safety and effectiveness of DSIP have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.

Source

What is the current state of research on DSIP?

While there are over 200 published studies on DSIP, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.

Source